These targetable RTK rearrangements consist of ALK fusion in lung cancer (5) and anaplastic large cell lymphoma (6), ROS1 fusion in lung cancer (7) and glioblastoma (8), RET fusion in lung (9) and thyroid cancer (10), FGFR fusion in bile duct (11) and urothelial carcinoma (12), as well as NTRK fusion in pan-cancer (13). Here, ROS1 is linked to lung carcinoma.